Nippon Shinyaku Co., Ltd., has been developing compounds in several therapeutic fields, including hematological malignancies and intractable/orphan diseases, in Japan/China and the US/EU. In the US, NS Pharma, Inc., has been developing NS-018 (for myelofibrosis) and NS-065/NCNP-01 (for Duchenne muscular dystrophy) on behalf of Nippon Shinyaku Co., Ltd.
|US : Phase I/II||NS-018||hematologic
|US : Phase II||NS-065/NCNP-01||intractable /
NCNP : National Center of Neurology and Psychiatry